BioSpace News Archive

RegeneRx Biopharmaceuticals, Inc. announced the publication of a new scientific study demonstrating a mechanism of action of thymosin beta 4 on human corneal epithelial cell migration and the downstream signaling pathways.

Trinity Health said this week that even nurses in a COVID-19 unit could not have N95 masks

The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, announced a new initiative that galvanizes its transatlantic network of academic institutions, foundations, and philanthropic partners to accelerate promising, near-term therapies to treat COVID-19 and its complications and battle future pandemic threats.

DOTmed.com, the world’s leading online medical equipment marketplace, is launching a free service to help hospitals across the country support one another in their efforts to combat the novel coronavirus.

Barry Byrne, MD, PhD, will serve as Chief Medical Advisor; John W. Day, MD, PhD and Matthew B. Harms, MD, to serve as Medical Consultants Dr. Byrne to lead a Facebook Live Conversation on Thursday, April 2 about how people living with muscular dystrophy, ALS and related neuromuscular diseases can navigate the world during the COVID-19 crisis

Adaptive Extends Immune Medicine Platform to Discover Therapeutic Antibodies From Recovered COVID-19 Patients Amgen Will Leverage Genetics, Immunology, Antibody Engineering and Manufacturing Capabilities Companies Will Begin Work Immediately

Accelerated Enrollment Solutions ( AES ), a business of PPD, Inc. (Nasdaq: PPD ), and Science 37 , a leader in virtual clinical trials, are collaborating to recruit and enroll clinical trial participants who live beyond the geographic location of tr

Flagship Pioneering, a unique life sciences innovation enterprise, announced that on March 27, it closed a $1.1 billion capital raise for its seventh Origination Fund to support the creation of Human Health and Sustainability companies originated and operating within its Flagship Labs unit.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions announced today that it was featured on a FOX segment titled, " Englewood pharmaceutical company looking to treat COVID